Endo has struggled lately to right the ship, and now it’s giving a new skipper a turn at the wheel.

More than two years after buying Merck's OTC unit and local player Dihon, bringing together three separate consumer care businesses in China remains a…

Allergan has shown recently that it may just intend to stick to the “stepping stone deals” script it’s been talking up--at least, for now. But that hasn’t…

Complicated drug formulations are generally viewed as a barrier to generic competition, but that is not stopping India's Glenmark from placing Celgene…

England’s cost watchdogs are changing their tune on Alexion’s rare bone disorder drug Strensiq--but not quite as much as the drugmaker would like.

While GlaxoSmithKline’s first-of-a-kind malaria vaccine, Mosquirix, is tied up with pilot projects, a competitor may be nearing in Sanaria’s PfSPZ.

Moderna Therapeutics, the much-ballyhooed Cambridge-based biotech developing a cutting-edge mRNA treatment platform, says it will build a $110 million…

Less than two weeks after a report highlighted complaints from agents at the FDA’s criminal office, a U.S. congressional committee has decided to take a closer…